A cephalosporin antibiotic that is administered intravenously or intramuscularly. It is active against most common gram-positive and gram-negative microorganisms, is a potent inhibitor of Enterobacteriaceae, and is highly resistant to hydrolysis by beta-lactamases. The drug has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.
Semisynthetic broad-spectrum cephalosporin.
One of the CEPHALOSPORINS that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms.
A species of gram-negative, facultatively anaerobic, rod-shaped bacteria that occurs in soil, fecal matter, and sewage. It is an opportunistic pathogen and causes cystitis and pyelonephritis.
Benzoate derivatives that contain one or more alkyl or aryl groups linked to the benzene ring structure by OXYGEN.
A pyridinium-substituted semisynthetic, broad-spectrum antibacterial used especially for Pseudomonas infections in debilitated patients.
A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.
Naturally occurring family of beta-lactam cephalosporin-type antibiotics having a 7-methoxy group and possessing marked resistance to the action of beta-lactamases from gram-positive and gram-negative organisms.
Semisynthetic wide-spectrum cephalosporin with prolonged action, probably due to beta-lactamase resistance. It is used also as the nafate.
A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid.
A cephalosporin antibiotic.
A group of glycine amides of aminobenzoic acids.
A hexosyltransferase involved in the transfer of disaccharide molecules to the peptidoglycan structure of the CELL WALL SKELETON. It plays an important role in the genesis of the bacterial CELL WALL.
A semisynthetic cephamycin antibiotic resistant to beta-lactamase.
Inorganic compounds that contain oxygen as an integral part of the molecule.
The sum of the weight of all the atoms in a molecule.
Anaerobic degradation of GLUCOSE or other organic nutrients to gain energy in the form of ATP. End products vary depending on organisms, substrates, and enzymatic pathways. Common fermentation products include ETHANOL and LACTIC ACID.
A flavoprotein and iron sulfur-containing oxidoreductase complex that catalyzes the conversion of UBIQUINONE to ubiquinol. In MITOCHONDRIA the complex also couples its reaction to the transport of PROTONS across the internal mitochondrial membrane. The NADH DEHYDROGENASE component of the complex can be isolated and is listed as EC 1.6.99.3.
A flavoprotein and iron sulfur-containing oxidoreductase that catalyzes the oxidation of NADH to NAD. In eukaryotes the enzyme can be found as a component of mitochondrial electron transport complex I. Under experimental conditions the enzyme can use CYTOCHROME C GROUP as the reducing cofactor. The enzyme was formerly listed as EC 1.6.2.1.
A group of oxidoreductases that act on NADH or NADPH. In general, enzymes using NADH or NADPH to reduce a substrate are classified according to the reverse reaction, in which NAD+ or NADP+ is formally regarded as an acceptor. This subclass includes only those enzymes in which some other redox carrier is the acceptor. (Enzyme Nomenclature, 1992, p100) EC 1.6.
A trace element with the atomic symbol Ni, atomic number 28, and atomic weight 58.69. It is a cofactor of the enzyme UREASE.
In bacteria, a group of metabolically related genes, with a common promoter, whose transcription into a single polycistronic MESSENGER RNA is under the control of an OPERATOR REGION.
Any of the processes by which cytoplasmic or intercellular factors influence the differential control of gene action in bacteria.
A loose confederation of computer communication networks around the world. The networks that make up the Internet are connected through several backbone networks. The Internet grew out of the US Government ARPAnet project and was designed to facilitate information exchange.
A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.
Substances that reduce the growth or reproduction of BACTERIA.
Vaccines or candidate vaccines used to prevent infection with VIBRIO CHOLERAE. The original cholera vaccine consisted of killed bacteria, but other kinds of vaccines now exist.
An acute diarrheal disease endemic in India and Southeast Asia whose causative agent is VIBRIO CHOLERAE. This condition can lead to severe dehydration in a matter of hours unless quickly treated.
Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.
The interactions between physician and patient.
Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.
An ENTEROTOXIN from VIBRIO CHOLERAE. It consists of two major protomers, the heavy (H) or A subunit and the B protomer which consists of 5 light (L) or B subunits. The catalytic A subunit is proteolytically cleaved into fragments A1 and A2. The A1 fragment is a MONO(ADP-RIBOSE) TRANSFERASE. The B protomer binds cholera toxin to intestinal epithelial cells, and facilitates the uptake of the A1 fragment. The A1 catalyzed transfer of ADP-RIBOSE to the alpha subunits of heterotrimeric G PROTEINS activates the production of CYCLIC AMP. Increased levels of cyclic AMP are thought to modulate release of fluid and electrolytes from intestinal crypt cells.
Use of plants or herbs to treat diseases or to alleviate pain.
The profession of writing. Also the identity of the writer as the creator of a literary production.
Collections of facts, assumptions, beliefs, and heuristics that are used in combination with databases to achieve desired results, such as a diagnosis, an interpretation, or a solution to a problem (From McGraw Hill Dictionary of Scientific and Technical Terms, 6th ed).
The guidelines and policy statements set forth by the editor(s) or editorial board of a publication.
Intentional falsification of scientific data by presentation of fraudulent or incomplete or uncorroborated findings as scientific fact.
"The business or profession of the commercial production and issuance of literature" (Webster's 3d). It includes the publisher, publication processes, editing and editors. Production may be by conventional printing methods or by electronic publishing.
Theoretical construct used in applied mathematics to analyze certain situations in which there is an interplay between parties that may have similar, opposed, or mixed interests. In a typical game, decision-making "players," who each have their own goals, try to gain advantage over the other parties by anticipating each other's decisions; the game is finally resolved as a consequence of the players' decisions.
An island republic of the West Indies. Its capital is Roseau. It was discovered in 1493 by Columbus and held at different times by the French and the British in the 18th century. A member of the West Indies Federation, it achieved internal self-government in 1967 but became independent in 1978. It was named by Columbus who discovered it on Sunday, Domingo in Spanish, from the Latin Dominica dies, the Lord's Day. (From Webster's New Geographical Dictionary, 1988, p338 & Room, Brewer's Dictionary of Names, 1992, p151)
A species of gram-negative, aerobic bacteria primarily found in purulent venereal discharges. It is the causative agent of GONORRHEA.
A third-generation cephalosporin antibiotic that is stable to hydrolysis by beta-lactamases.
Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses).
A genus of gram-negative, aerobic, coccoid bacteria whose organisms are part of the normal flora of the oropharynx, nasopharynx, and genitourinary tract. Some species are primary pathogens for humans.
A species of gram-negative, aerobic BACTERIA. It is a commensal and pathogen only of humans, and can be carried asymptomatically in the NASOPHARYNX. When found in cerebrospinal fluid it is the causative agent of cerebrospinal meningitis (MENINGITIS, MENINGOCOCCAL). It is also found in venereal discharges and blood. There are at least 13 serogroups based on antigenic differences in the capsular polysaccharides; the ones causing most meningitis infections being A, B, C, Y, and W-135. Each serogroup can be further classified by serotype, serosubtype, and immunotype.
All of the divisions of the natural sciences dealing with the various aspects of the phenomena of life and vital processes. The concept includes anatomy and physiology, biochemistry and biophysics, and the biology of animals, plants, and microorganisms. It should be differentiated from BIOLOGY, one of its subdivisions, concerned specifically with the origin and life processes of living organisms.
Sequential operating programs and data which instruct the functioning of a digital computer.
The portion of an interactive computer program that issues messages to and receives commands from a user.
A procedure consisting of a sequence of algebraic formulas and/or logical steps to calculate or determine a given task.
A field of biology concerned with the development of techniques for the collection and manipulation of biological data, and the use of such data to make biological discoveries or predictions. This field encompasses all computational methods and theories for solving biological problems including manipulation of models and datasets.
The field which deals with illustrative clarification of biomedical concepts, as in the use of diagrams and drawings. The illustration may be produced by hand, photography, computer, or other electronic or mechanical methods.

Levels of cefmenoxime in sera and peritoneal tissues of patients undergoing gastrointestinal surgery. (1/55)

It is not known whether a prophylactic antibiotic administered prior to surgery reaches adequate levels in the peritoneum, where peritonitis may take place. This study determined levels of cefmenoxime in sera and peritoneal tissues of patients undergoing gastrointestinal surgery. Fifteen patients who underwent elective gastrointestinal surgery received an intravenous drip infusion of cefmenoxime (2 g) over 1 h prior to surgery. In patients who underwent gastrectomy, the level of cefmenoxime in serum was 130.8 +/- 6.9 micrograms/ml at laparatomy and decreased to 5.0 +/- 0.7 micrograms/ml at 4 h. Levels in parietal peritoneal and omental tissues at laparotomy were 35.3 +/- 5.2 and 19.2 +/- 3.5 micrograms, respectively, and decreased time dependently. In patients who underwent cholecystectomy, the level of cefmenoxime in serum was 137.9 +/- 7.3 micrograms/ml at laparotomy and decreased to 5.0 +/- 1.2 micrograms/ml at 4 h. Levels in parietal peritoneal and omental tissues were 31.0 +/- 8.4 and 13.7 +/- 3.3 micrograms/g, respectively, and decreased time dependently. The level of cefmenoxime in serum correlated with the levels of cefmenoxime in parietal peritoneum (r = 0.64, P less than 0.01) and in omentum (r = 0.47, P less than 0.02). In patients with appendicitis who received a bolus injection of 2 g of cefmenoxime, the level of drug in inflammatory omental tissue correlated with the level in serum. The levels in peritoneal tissue during surgery lasting up to 2 h were significantly greater than in MIC of cefmenoxime against almost all bacteria reported. A preoperative single dose of 2 g of cefmenoxime probably is effective as a prophylactic for intraoperative contamination.  (+info)

Synergistic effects of romurtide and cefmenoxime against experimental Klebsiella pneumonia in mice. (2/55)

We investigated the synergistic effects of romurtide (MDP-Lys [L18]) and cefmenoxime (CMX) in the treatment of experimental Klebsiella pneumonia in mice. Mice were infected with 1 x 10(4) CFU of Klebsiella pneumoniae by inhalation of aerosol bacterial suspension. About 90% of untreated animals died within a week; however, the mortality rate of animals treated with CMX alone at a dose of 40 mg/kg/day was 60% at 7 days after the infection. When one or two doses of L18 were administered before or after the infection concomitantly with CMX, a remarkable improvement in the survival rate was observed. There was no significant improvement in the survival rate of animals treated with L18 alone before or after infection. Histopathological sections of the lungs of mice treated with CMX and L18 showed slower progression of infection than those of mice treated with CMX alone. Significant differences were also found in quantitative cultures of viable bacteria in the lungs 1 to 4 days after the infection. Although viable bacterial counts in the lungs of the control and CMX-treated groups showed a rapid increase 24 to 48 h after the infection, they remained lower than the initial counts (x 10(4)) in the lungs of mice treated with combination regimens. From these results, it can be concluded that L18 is a useful biological response modifier in the treatment of acute pulmonary bacterial infections.  (+info)

Studies on condensed-heterocyclic azolium cephalosporins. III. Synthesis and antibacterial activity of 7 beta-[2-(2-amino-5-substituted-thiazol-4-yl)-2 (Z)-alkoxyiminoacetamido]-3-(condensed-heterocyclic azolium)methyl-3-cephem-4- carboxylates. (3/55)

As a part of our research on the synthesis of cephalosporins bearing condensed-heterocyclic azolium groups at the 3 position in the cephalosporin nucleus, we describe herein the synthesis of 7 beta-[2-(2-amino-5-halogeno-, methylthio-, methylsulfinyl-, methylsulfonyl- and sulfothiazol-4-yl)-2(Z)-alkoxyiminoacetamido] cephalosporins and their antibacterial activity. Among the compounds prepared, 7 beta-[2-(2-amino-5-chlorothiazol-4-yl)-2(Z)- methoxyiminoacetamido]-3-(imidazo[1,5-a]-pyridinium-1-yl)methyl-3-cephem -4-carboxylate (14) showed good antibacterial activity against both Staphylococcus aureus including methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa, whereas the antibacterial activity against other Gram-negative bacteria was a slightly lower than that of 7 beta-[2-(2-aminothiazol-4-yl)-2(Z)-methoxyiminoacetamido]-3-(im ida zo [1,2-a]pyridinium (I-1) and imidazo[1,5-a]pyridinium (I-4)-1-yl)methyl-3-cephem-4-carboxylates.  (+info)

Application of mathematical model to multiple-dose experimental chemotherapy for fatal murine pneumonia. (4/55)

Two beta-lactam antibiotics, cefazolin and cefmenoxime, were administered for 7 days to mice with pneumonia caused by Klebsiella pneumoniae by using dosage regimens that would simulate multiple dosing in usual clinical treatments at dosing intervals of 8 or 12 h. Viable numbers of the bacteria in the lungs were measured at 12- or 24-h intervals. The mathematical model established in a previous single-dose study was applied in this study to explain the time courses of the changes in bacterial count over 7 days. However, because the error in viable count measurements was larger than that in the previous study, the time course of the changes in mean viable count was not regular and the viable count reduction rate changed during multiple dosing, and therefore it was difficult to explain the time course by repeated application of the mathematical model described previously. This study suggests that the changes in pharmacokinetic and pharmacodynamic parameters during multiple dosing need to be considered.  (+info)

Paradoxical activity of beta-lactam antibiotics against Proteus vulgaris in experimental infection in mice. (5/55)

In previous papers (Y. Ikeda and T. Nishino, Antimicrob. Agents Chemother. 32:1073-1077, 1988; Y. Ikeda, T. Nishino, and T. Tanino, Antimicrob. Agents Chemother. 31:865-869, 1987), we reported that many of the 7-aminothiazolyl cephalosporins, such as cefmenoxime, showed paradoxically reduced activity against Proteus vulgaris at higher concentrations, whereas these paradoxical effects were not observed for other types of cephalosporins, such as cefbuperazone and cefoperazone. In this study, we compare the therapeutic effect of cefmenoxime with that of cefbuperazone and explore the in vivo paradoxical effect of cefmenoxime by using an experimental infection model in mice. In an intraperitoneal infection with P. vulgaris 11, the survival rate with cefmenoxime was increased to 43% at 3.13 mg/kg but was lower at higher doses. On the other hand, cefbuperazone did not show such a paradoxical therapeutic effect. In mice infected with P. vulgaris 11, cefmenoxime levels in both serum and peritoneal washings were rapidly reduced and beta-lactamase activities in the peritoneal cavity were increased at higher cefmenoxime doses. These findings suggested that high levels of cefmenoxime at the infection site induced increased production of beta-lactamase, which then rapidly inactivated the antibiotic. We conclude that the paradoxical therapeutic effect of cefmenoxime against P. vulgaris occurs by the same mechanisms as the in vitro effect and that the high beta-lactamase inducibility and low beta-lactamase stability may account for the paradoxical therapeutic effect of cefmenoxime against P. vulgaris.  (+info)

Application of mathematical model to experimental chemotherapy of fatal murine pneumonia. (6/55)

Two beta-lactam antibiotics, cefazolin and cefmenoxime, were administered in an experimental model of murine pneumonia caused by Klebsiella pneumoniae in a way which enabled us to approximate the serum antibiotic concentration time course in humans. Bacterial counts during the experiments were subjected to nonlinear least-squares analyses by using a mathematical model that explained the bacterial killing by the antibiotic concentration time course and other factors associated with antimicrobial potency and bacterial growth. Cefazolin gave a killing curve that changed synchronously with the drug levels in serum; in contrast, cefmenoxime gave a curve that was prolonged as compared with the change in the drug levels in serum. Multiple correlation coefficients were about 0.9, and the model worked well for bacterial count data. Parameters relating to antimicrobial potency of the drugs, bacterial growth rate, and drug distribution into the tissue were estimated numerically.  (+info)

In vitro assessment of the cytotoxicity of six topical antibiotics to four cultured ocular surface cell lines. (7/55)

To determine the cytotoxicity of antibiotic eyedrops to ocular surface cells using a semi-quantitative method, a range of commercially available antibiotic eyedrops were assessed by using three corneal cell lines and one conjunctival cell line. All antibiotic solutions were free of benzalkonium chloride. Cell viability was determined by the MTT assay and neutral red assay following the exposure of cells to the undiluted, 2- and 10-fold diluted drugs for 10, 30, and 60 min. Toxicity was compared using % cell viability score (%CVS) . The tested eyedrops and values of %CVS50 and %CVS40/80 were Bestron((R)) (cefmenoxime, 100, 94) , Panimycin((R)) (dibekacin, 86, 58) , Noflo((R)) (norfloxacin, 90, 50) , Cravit((R)) (levofloxacin, 86, 46) , Tosfulo((R)) (tosufloxacin, 57, -3) , and Vigamox((R)) (moxifloxacin, 57, -6) . Cell viability markedly increased after dilution. For instance, cell viability assayed by MTT was > 80% for all the measurements in antibiotics diluted 10-fold, and the rate of the measurements showing > 80% cell viability decreased to 43% (31 out of 72 measurements) in the solutions diluted 2-fold. Of the drugs tested, Bestron((R)) containing cefmenoxime showed the weakest toxicity. Vigamox((R)) containing moxifloxacin and Tosuflo((R)) containing tosufloxacin were more toxic when compared with the other antibiotics. CVS was useful for the comparison of the cytotoxicity of the drugs.  (+info)

Antimicrobial activity and stability to beta-lactamase of BMY-28271, a new oral cephalosporin ester. (8/55)

BMY-28271, the acetoxyethyl ester of BMY-28232, 7-[(Z)-2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3(Z) -propen-1-yl-3- cephem-4-carboxylic acid, is a new oral cephalosporin. BMY-28232 has a widely expanded spectrum with high activity against gram-positive and gram-negative bacteria. BMY-28232 is far more active than cefixime or cefteram against Staphylococcus aureus and Staphylococcus epidermidis. Against gram-negative bacteria, the activity of BMY-28232 was comparable to or somewhat weaker than that of cefixime or cefteram. BMY-28232 was a poor substrate for various beta-lactamases. Orally administered BMY-28271 had a good therapeutic effect on systemic infections with S. aureus and some gram-negative bacteria in mice. Oral BMY-28271 was efficacious against S. aureus Smith infection: the efficacy of BMY-28271 was 80 to 90 times higher than that of cefixime or cefteram.  (+info)

[Study of clinical bacteriological efficacy in a cefmenoxime ototopical solution].: One percent cefmenoxime (CMX) ototopical solution was administered to 302 pa
Cefmenoxime is a medicine available in a number of countries worldwide. A list of US medications equivalent to Cefmenoxime is available on the Drugs.com website.
Product Number , 78097775. CAS Number , 75738-58-8. EC , Molecular Formula , C16H18ClN9O5S3. Molecular Weight , 548.02. Storage Temp , Harmonized Tariff code , 29419000. Signal Word , ...
Clinivex is a high quality reference standard supplier of 2-(2-Aminothiazol-4-yl)acetic Acid-13C,15N2 Hydrochloride, CAS no - . View more information regarding 2-(2-Aminothiazol-4-yl)acetic Acid-13C,15N2 Hydrochloride, including solubility, MSDS & more.
1LSP: Structure of a bulgecin-inhibited g-type lysozyme from the egg white of the Australian black swan. A comparison of the binding of bulgecin to three muramidases.
In Japan, Neisseria gonorrhoeae, a sexually transmitted pathogen, has recently shown significant resistance to various antimicrobial agents. In this study, a checkerboard method was utilized to investigate the in vitro activities of cefixime (CFIX), cefteram (CFTM), or amoxicillin (AMPC) in combinat …
Synthesis and structure-activity relationships of 7.BETA.-[2-(2-aminothiazol-4-yl)acetamido]-cephalosporin derivatives. III. Synthesis and antibacterial activity of 7.BETA.-[2-amino-2-(2-aminothiazol-4-yl)acetamido]cephalosporins.:III. SYNTHESIS AND ANTIBACTERIAL ACTIVITY OF 7β-[2-AMINO- 2-(2-A MINOTHIAZOL-4-YL)ACETAMIDO]CEPHALOSPORINS (1980 ...
A new broad-spectrum generation wormer for pigs that can be administered through drinking water has been launched at the Pig and Poultry Fair 2012.
We,China 7-AMINO-3-CHLOROMETHYL-3-CEPHEM-4-CARBOXYLIC ACID P-METHOXYBENZYL ESTER, HYDROCHLORIDE 113479-65-5;115369-44-3 Suppliers and China 7-AMINO-3-CHLOROMETHYL-3-CEPHEM-4-CARBOXYLIC ACID P-METHOXYBENZYL ESTER, HYDROCHLORIDE 113479-65-5;115369-44-3 Manufacturers, provide 7-AMINO-3-CHLOROMETHYL-3-CEPHEM-4-CARBOXYLIC ACID P-METHOXYBENZYL ESTER, HYDROCHLORIDE 113479-65-5;115369-44-3 product and the products related with China 7-AMINO-3-CHLOROMETHYL-3-CEPHEM-4-CARBOXYLIC ACID P-METHOXYBENZYL ESTER, HYDROCHLORIDE 113479-65-5;115369-44-3 - Otsuka Chemical
Doctors give trusted answers on uses, effects, side-effects, and cautions: Dr. Khairullah on nitrofurantoin side effects: Outside of allergic reactions, which are not unique to cefdinir, none of the cephalosporins have side-effects which are very significant. They include cases of gastrointestinal discomfort with nausea, vomiting and diarrhea and rash as occasional occurrences. Sold as omnicef, it is one of several oral cephalosporins.
InChI=1S/C14H15N5O5S2/c1-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24-2)6-4-26-14(15)16-6/h4,8,12H,3H2,1-2H3,(H2,15,16)(H,17,20)(H,22,23)/b18-7-/t8-,12-/m1/ ...
an oral cephalosporin (trade names Keflex and Keflin and Keftab) commonly prescribe for mild to moderately severe infections of the skin or ears or throat or lungs or urinary tract. ...
These include latamoxef (moxalactam), cefmenoxime, cefoperazone, cefamandole, cefmetazole, and cefotetan. This is thought to be ...
The first products TAP file new drug applications for, were two cephalosporins, cefmenoxime (Cefmax) and cefsulodin (Cefonomil ...
Cefmax cefmenoxime (INN) cefmepidium chloride (INN) cefmetazole (INN) cefminox (INN) Cefobid cefodizime (INN) cefonicid (INN) ...
... cefmenoxime MeSH D02.065.589.099.249.190.190.135 - cefotiam MeSH D02.065.589.099.249.190.190.145 - ceftizoxime MeSH D02.065. ...
... cefmenoxime, cefmetazole, cefonicid, cefoperazone, cefotetan, ceftriaxone, and latamoxef (moxalactam); thought to be due to ...
Example of such sodium salts are (selection): Bispyribac, bithionol, bosentan, brequinar, bromfenac, Cefmenoxime, ceftiofur, ...
J01DC14 Flomoxef J01DD01 Cefotaxime J01DD02 Ceftazidime J01DD03 Cefsulodin J01DD04 Ceftriaxone J01DD05 Cefmenoxime J01DD06 ...
... cefmenoxime 1983 - ceftazidime 1983 - ceftizoxime 1983 - norfloxacin 1984 - cefonicid 1984 - cefotetan 1984 - temocillin 1985 ...
... is a third-generation cephalosporin antibiotic. Diseases Database (DDB): 30892 Yokota N, Koguchi M, Suzuki Y, ... Duncker G, Reich U, Krausse R (1994). "Cefmenoxime in corneal organ culture". Ophthalmologica. 208 (5): 262-6. doi:10.1159/ ... Paladino J, Fell R (1994). "Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial ... Fukayama S, Ishihara R, Deguchi K, Oda S, Tanaka S, Nakane Y, Fukumoto T (1995). "Antibacterial activities of cefmenoxime ...
InChI=1S/C20H22N4O10S/c1-9(25)33-10(2)34-19(28)15-11(7-32-20(21)29)8-35-18-14(17(27)24(15)18)22-16(26)13(23-30-3)12-5-4-6-31-12/h4-6,10,14,18H,7-8H2,1-3H3,(H2,21,29)(H,22,26)/b23-13-/t10?,14-,18-/m1/ ...
The production of benzylpenicillin involves fermentation, recovery and purification of the penicillin.[10] The fermentation process of the production of benzylpencillin is about obtaining the product. The presence of the product in solution inhibits the reaction and reduces the product rate and yield. Thus, in order to obtain the most product and increase the rate of reaction the product, would be continuously extracted out.[11] This is done by having the mold with either glucose, sucrose, lactose, startch, or detrin, nitrate, ammonium salt, corn steep liquor, peptone, meat or yeast extract, and little amounts of inorganic salts.[12] The recovery of the benzylpencillin is the most important part of the production process because it affects the purification steps if done wrong.[10] There are many different types of techniques to recover benzyl penicillin, aqueous two-phase extraction, liquid membrane extraction, microfiltration technique, and solvent subulation[10] Extraction is more commonly ...
... , sold under the brandname Merrem among others, is a broad-spectrum antibiotic used to treat a variety of bacterial infections.[1] Some of these include meningitis, intra-abdominal infection, pneumonia, sepsis, and anthrax.[1] It is given by injection into a vein.[1] Common side effects include nausea, diarrhea, constipation, headache, rash, and pain at the site of injection.[1] Serious side effects include Clostridium difficile infection, seizures, and allergic reactions including anaphylaxis.[1] Those who are allergic to other β-lactam antibiotics are more likely to be allergic to meropenem.[1] Use in pregnancy appears to be safe.[1] It is in the carbapenem family of medications.[1] Meropenem usually results in bacterial death through blocking their ability to make a cell wall.[1] It is more resistant to breakdown β-lactamase producing bacteria.[1] Meropenem was patented in 1983.[2] It was approved for medical use in the United States in 1996.[1] It is on the World Health ...
InChI=1S/C14H15N5O5S2/c1-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24-2)6-4-26-14(15)16-6/h4,8,12H,3H2,1-2H3,(H2,15,16)(H,17,20)(H,22,23)/b18-7-/t8-,12-/m1/ ...
Bonow RO, Carabello BA, Kanu C, et al. (August 2006). "ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons". Circulation. 114 (5): e84-231. doi:10.1161/CIRCULATIONAHA.106.176857. PMID 16880336 ...
Penicillin V is sometimes used in the treatment of odontogenic infections.. It is less active than benzylpenicillin (penicillin G) against Gram-negative bacteria.[9][10] Phenoxymethylpenicillin has a range of antimicrobial activity against Gram-positive bacteria that is similar to that of benzylpenicillin and a similar mode of action, but it is substantially less active than benzylpenicillin against Gram-negative bacteria.[9][10]. Phenoxymethylpenicillin is more acid-stable than benzylpenicillin, which allows it to be given orally.. Phenoxymethylpenicillin is usually used only for the treatment of mild to moderate infections, and not for severe or deep-seated infections since absorption can be unpredictable. Except for the treatment or prevention of infection with Streptococcus pyogenes (which is uniformly sensitive to penicillin), therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response.[11] People treated initially with parenteral ...
The in vitro activity of ceftolozane-tazobactam has been examined in five surveillance studies of isolates from Europe and North America.[8] In these studies, ceftolozane-tazobactam was notable for its activity against Pseudomonas aeruginosa, a moderately common cause of hospital-acquired infections that is commonly multi-drug resistant. Ninety percent of P. aeruginosa isolates were inhibited by a ceftolozane-tazobactam at a concentration of 4 μg/mL (MIC90), making it the most potent anti-pseudomonal antibiotic in clinical use. In these same studies, ceftolozane-tazobactam exhibited MIC90 values of ,1 μg/mL for Escherichia coli, Citrobacter koseri, Morganella morganii, Proteus mirabilis, Salmonella species, and Serratia marcescens. Somewhat poorer activity is observed for the Klebsiella and Enterobacter species, with the MIC90 for extended spectrum beta-lactamase (ESBL) expressing Klebsiella pneumonia being ,32 μg/mL. ...
A set of multienzymes (peptide synthase CepA, CepB, and CepC) are responsible for assembling the heptapeptide. (Figure 2). The organization of CepA, CepB, and Cep C closely resembles other peptide synthases such as those for surfactin (SrfA1, SrfA2, and SrfA3) and gramicidin (GrsA and GrsB).[41] Each peptide synthase activates codes for various amino acids to activate each domain. CepA codes for modules 1, 2, and 3. CepB codes for modules 4, 5, and 6, and CepC codes for module 7. The three peptide synthases are located at the start of the region of the bacterial genome linked with antibiotic biosynthesis, and span 27 kb.[41]. After the linear heptapeptide molecule is synthesized, vancomycin has to undergo further modifications, such as oxidative cross-linking and glycosylation, in trans[clarification needed] by distinct enzymes, referred to as tailoring enzymes, to become biologically active (Figure 3). To convert the linear heptapeptide, eight enzymes, open reading frames (ORFs) 7, 8, 9, 10, ...
InChI=1S/C16H21N7O7S3/c1-22-15(19-20-21-22)33-4-7-3-32-14-16(30-2,13(29)23(14)10(7)12(27)28)18-9(24)6-31-5-8(17)11(25)26/h8,14H,3-6,17H2,1-2H3,(H,18,24)(H,25,26)(H,27,28)/t8-,14-,16+/m1/s1 ‹See TfM› ...
... (SEF-di-nir) is a third-generation oral cephalosporin antibiotic sold under the brand names Cefzon and Omnicef. As of 2008, cefdinir, as Omnicef, was the highest-selling cephalosporin antibiotic in the United States, with more than US$585 million in retail sales of its generic versions alone.[1] Cefdinir is structurally similar to cefixime. It was discovered by Fujisawa Pharmaceutical Co., Ltd. (now Astellas) and introduced in 1991 under the brand name Cefzon.[2][3] Warner-Lambert licensed this cephalosporin for marketing in US from Fujisawa.[4] Abbott obtained U.S. marketing rights to Omnicef (cefdinir) in December 1998 through an agreement with Warner-Lambert Company.[5] It was approved by FDA on Dec 4, 1997.[6] It is available in US as Omnicef by Abbott Laboratories and in India as Cednir by Abbott, Kefnir by Glenmark, Cefdair by Xalra Pharma and Cefdiel by Ranbaxy. ...
Ceftolozane exerts bactericidal activities against susceptible gram-negative and gram-positive infections by inhibiting essential penicillin-binding proteins (PBPs), which are required for peptidoglycan cross-linking for bacterial cell wall synthesis, resulting in inhibition of cell wall synthesis and subsequent cell death. Ceftolozane is an inhibitor of PBPs of Pseudomonas aeruginosa (e.g. PBP1b, PBP1c, and PBP3) and E. coli (e.g., PBP3).[6][7] Tazobactam is a potent β-lactamase inhibitor of most common class A and C β-lactamases. Tazobactam has little clinically relevant in vitro activity against bacteria due to its reduced affinity to penicillin-binding proteins; however, it is an irreversible inhibitor of some β-lactamases (certain penicillinases and cephalosporinases) and can covalently bind to some chromosomal and plasmid-mediated bacterial beta-lactamases.[6] The addition of tazobactam strengthens the therapeutic response to ceftolozane, giving it the ability to treat a broader range ...
... is a second-generation cephalosporin antibiotic. It can be used to treat ear infections, skin infections, and other bacterial infections.[citation needed] It comes as a tablet and as a liquid suspension. Although there is a widely quoted cross-allergy risk of 10% between cephalosporins and penicillin, an article[1] has shown no increased risk for cross-allergy for cefprozil and several other second-generation or later cephalosporins. It was patented in 1983 and approved for medical use in 1992.[2] ...
... has the ability to kill a wide variety of bacteria. Imipenem is the active antibiotic agent and works by interfering with their ability to form cell walls, so the bacteria break up and die. Imipenem is rapidly degraded by the renal enzyme dehydropeptidase if administered alone (making it less effective); the metabolites can cause kidney damage.[11] Imipenem is a broad-spectrum betalactam antibiotic used for severe bacterial infections caused by susceptible organisms. Because imipenem is rapidly inactivated by renal dehydropeptidase I, it is given in combination with cilastatin, a DHP-I inhibitor which increases half-life and tissue penetration of imipenem. Imipenem/cilastatin, like other carbapenems, binds to bacterial penicillin-binding proteins and interferes with bacterial cell wall integrity and synthesis. It has activity against many aerobic and anaerobic Gram-positive and Gram-negative organisms, including Staphylococcus aureus, Streptococcus pyogenes, S. agalactiae, S. ...
Cefmenoxime • Cefodizime • Cefotaxime • Cefpimizole • Cefpiramide • Cefpodoxime • Cefsulodin • Cefteram • Ceftibuten • ...
... s such as metronidazole, tinidazole, cephamandole, latamoxef, cefoperazone, cefmenoxime, and furazolidone, cause a ...
InChI=1S/C14H24N2O7/c1-5-4-6(17)14(20)13(21-5)22-12-10(19)7(15-2)9(18)8(16-3)11(12)23-14/h5,7-13,15-16,18-20H,4H2,1-3H3/t5-,7-,8+,9+,10+,11-,12-,13+,14+/m1/s1 ...
سفتریاکسون (آیوپاک آدی: (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-,2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, اینگیلیسجه: Ceftriaxone, (چینجه:頭孢曲松‎)، عربجه: سيفترياكسون‎، روسجا: Цефтриаксон) بیر شیمیایی بیلشیک دواء. بۇ دواءنین مول جرمیسی مول/قرم ۵۵۴٫۵۸ دیر. نیمه عمر یا یاریلانما سۆرعتی ۵٫۸-۸٫۷ ساعات زامان آپاریر و آنتی‌بیوتیک‌ اۆچون ایستیفاده اوْلونور. ...
سیکلوسرین (آیوپاک آدی: (R)-4-Amino-1,2-oxazolidin-3-one, اینگیلیسجه: Cycloserine, عربجه: سيكلوسيرين‎، روسجا: Циклосерин) بیر شیمیایی بیلشیک دواء. بۇ دواءنین مول جرمیسی مول/قرم ۱۰۲٫۰۹۲ دیر. متابولیسمی قاراجییرده باش وئریر. سیکلوسرین آنتی‌بیوتیک‌ اۆچون ایستیفاده اوْلونور. ...
Cefmenoxime • Cefodizime • Cefotaxime • Cefpimizole • Cefpiramide • Cefpodoxime • Cefsulodin • Cefteram • Ceftibuten • ...
سیلور سولفادیازین (آیوپاک آدی: Silver [(4-aminophenyl)sulfonyl](pyrimidin-2-yl)azanide, اینگیلیسجه: Silver sulfadiazine, (چینجه:磺胺嘧啶银‎)) بیر شیمیایی بیلشیک دواء. بۇ دواءنین مول جرمیسی مول/قرم ۳۵۷٫۱۴ دیر. سیلور سولفادیازین آنتی‌بیوتیک‌ اۆچون ایستیفاده اوْلونور. ...
Cefmenoxime is a third-generation cephalosporin antibiotic. Diseases Database (DDB): 30892 Yokota N, Koguchi M, Suzuki Y, ... Duncker G, Reich U, Krausse R (1994). "Cefmenoxime in corneal organ culture". Ophthalmologica. 208 (5): 262-6. doi:10.1159/ ... Paladino J, Fell R (1994). "Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial ... Fukayama S, Ishihara R, Deguchi K, Oda S, Tanaka S, Nakane Y, Fukumoto T (1995). "Antibacterial activities of cefmenoxime ...
Cefmenoxime , Monograph containing literature references, physical and biological properties and relevant information ...
A list of US medications equivalent to Cefmenoxime is available on the Drugs.com website. ... Cefmenoxime is a medicine available in a number of countries worldwide. ...
Cefmenoxime: Search drug information, interaction, images & medical diagnosis. The most comprehensive database of medicines ... Description: Cefmenoxime inhibits final cross-linking stage of peptidoglycan production through binding and inactivation of ... Disclaimer: This information is independently developed by MIMS based on Cefmenoxime from various references and is provided ...
The name cefmenoxime applies to the isomer having a syn-methoxyimino group. Prepn (unspecified stereochemistry): M. Ochiai et ...
Product Number , 78097775. CAS Number , 75738-58-8. EC , Molecular Formula , C16H18ClN9O5S3. Molecular Weight , 548.02. Storage Temp , Harmonized Tariff code , 29419000. Signal Word , ...
Cefmenoxime. Cefmenoxime hydrochloride (a derivative of Cefmenoxime) is reported as an ingredient of En Nuo Ni in the following ...
Harvengt, C.. Carboplatin, Cefmenoxime, Zidovudine. In: Acta Clinica Belgica (Multilingual Edition), Vol. 42, no. 6, p. 468-472 ...
One percent cefmenoxime (CMX) ototopical solution was administered to 302 pa ... Study of clinical bacteriological efficacy in a cefmenoxime ototopical solution].: ... Study of clinical bacteriological efficacy in a cefmenoxime ototopical solution].. Authors * Deguchi, K ... One percent cefmenoxime (CMX) ototopical solution was administered to 302 patients with purulent otitis media and acute diffuse ...
Cefmenoxime: clinical evaluation.. Baker RL, Perkins RL.. Am J Med. 1984 Dec 21;77(6A):53-9. ...
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are receiving this vaccine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.. Receiving this vaccine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.. ...
Role for dual individualization with cefmenoxime.. Cefmenoxime concentration/effect relationships were retrospectively explored ... Role for dual individualization with cefmenoxime. Schentag, J.J., Smith, I.L., Swanson, D.J., DeAngelis, C., Fracasso, J.E., ... The effects of cefmenoxime concentrations on in vitro growth kinetics of 21 isolated pathogens were studied using the Abbott MS ... Bacterial eradication rates could be described from cefmenoxime pharmacokinetics in the patient and from the relation between ...
DB00267, Cefmenoxime. DB00274, Cefmetazole. DB01328, Cefonicid. DB01329, Cefoperazone. DB01331, Cefoxitin. DB00430, ... DB00267, Cefmenoxime. DB00274, Cefmetazole. DB01328, Cefonicid. DB01329, Cefoperazone. DB01331, Cefoxitin. DB00430, ...
Cefmenoxime / analogs & derivatives * Cefmenoxime / pharmacology * Drug Synergism * Humans * Male * Neisseria gonorrhoeae / ...
Cefmenoxime Hydrochloride is a cephalosporin antibiotic that is administered intravenously or intramuscularly. Learn More ... Cefmenoxime hydrochloride Catalog No. A16156. Quick View .category-products .products-list .btn-quickcart { background: white; ...
0.5% Cefmenoxime hydrochloride and 1.0% sulbenicillin sodium eye drops. 1. -. 0.25% Chloramphenicol and 0.8% colistin sodium ... 0.3% OFLX eye drops and 0.5% cefmenoxime hydrochloride eye drops. 1. -. Yes. ...
Cefmenoxime. approved. yes. inhibitor. Details. DB00301. Flucloxacillin. approved, investigational. yes. inhibitor. Details. ...
These include latamoxef (moxalactam), cefmenoxime, cefoperazone, cefamandole, cefmetazole, and cefotetan. This is thought to be ...
Cefmenoxime hydrochloride An antibacterial 75738-58-8. sc-278818 25 mg. $196.00 0 ...
cefmenoxime 2 g P J01DD06 latamoxef 4 g P J01DD07 ceftizoxime 4 g P ...
Possible Involvement of Phospholipase D,Protein Kinase C and Polyol Pathway in Hyperproliferation and Hypertrophy of Cultured Vascular Smooth Muscle Cells Induced by High Glucose (1997 ...
EFFECT OF MIDECAMYCIN ACETATE ON INTESTINAL BACTERIAL FLORA OF CHILDREN, AND RESULTS OF CLINICAL STUDY ON MIDECAMYCIN ACETATE IN TREATMENT OF MYCOPLASMAL PNEUMONIA (1982 ...
Observation on the MICS and cefmenoxime disc susceptibility test. Jpn J Antibiot 37 : 791-801. ... Clinical laboratory approach for estimating effective administration of dosage of cefmenoxime. ...
Cefmenoxime (Cefmax) 7. cefpiramide 8. Gentamicins (Gentamicin) 9. Rifampin (Rifampicin) 10. Inulin ...
Cefepime Hydrochloride; Cefetecol; Cefixime; Cefmenoxime Hydrochloride; Cefmetazole; Cefmetazole Sodium; Cefonicid Monosodium; ...
Cefmenoxime: in vitro activity. Stamm, J.M. Am. J. Med. (1984) [Pubmed] ... The minimum inhibitory concentration (MIC) of cefmenoxime required to inhibit at least 90 percent of strains tested (MIC90) ...
cefmenoxime) , ceftazidimes (ceftazidime, cefpirome, cefepime) , cefalexins (cefalexin, cefaclor, cefadroxil, cefradine, ...
Role of dual individualization with cefmenoxime. Am. J. Med.77:43-50. ...
Hypoprothrombinemia (deficiency of prothrombin in the blood) is common with cefoperazone, cefamandole, cefotetan, cefmenoxime11 ...
  • Cefmenoxime Hydrochloride is a cephalosporin antibiotic that is administered intravenously or intramuscularly. (adooq.com)
  • Haisco Pharma's firstaid drugs comprise cefotene hydrochloride, sodium fusidate, cefmetazole sodium, cefmenoxime hydrochloride and cefoperazone sodium tazobactam sodium. (bioportfolio.com)
  • The drug brand named Tacef contains generic salt-Cefmenoxime Hydrochloride and is manufactured by Grunenthal. (drug-info.in)
  • Cefmenoxime is a third-generation cephalosporin antibiotic. (wikipedia.org)
  • Mathematical examination of dual individualization principles (I): relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. (springer.com)
  • Mathematical examination of dual individualization principles (II): the rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime. (springer.com)
  • Based on results of the MTT assay and CVS, the order of cell viability after exposure to the antibiotic solutions was cefmenoxime ≥ tosufloxicin ≥ dibekacin ≥ levofloxacin ≥ norfloxacin = gatifloxacin = moxifloxacin. (dovepress.com)
  • Cefmenoxime (SCE-1365), a novel broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities. (asm.org)
  • Effect of probenecid on the pharmacokinetics of cefmenoxime. (ecba.info)
  • related structurally to cefotaxime and ceftizoxime, q.q.v. The name cefmenoxime applies to the isomer having a syn- methoxyimino group. (drugfuture.com)
  • Study of clinical bacteriological efficacy in a cefmenoxime o. (mysciencework.com)
  • Cefmenoxime: clinical evaluation. (nih.gov)
  • the rate of bacterial eradication at the same area under the inhibitory curve is more rapid for Ciprofloxacin than for Cefmenoxime. (usc.edu)
  • Auflage actorshortname group cefmenoxime shopping. (lusospace.com)
  • One percent cefmenoxime (CMX) ototopical solution was administered to 302 patients with purulent otitis media and acute diffuse external otitis in open study fashion, and to 216 patients with purulent otitis media in double blind condition. (mysciencework.com)
  • Disclaimer: This information is independently developed by MIMS based on Cefmenoxime from various references and is provided for your reference only. (mims.com)